Cleo Diagnostics logo

CLEO Diagnostics Takes Ovarian Cancer Test from Lab to Commercialisation Phase, Says OCRF

ASX-listed Cleo Diagnostics is currently working to improve ovarian cancer diagnosis, with the potential to reduce unnecessary surgery.

A more accurate test for ovarian cancer is now being taken from the lab bench into clinical use by Australian company Cleo Diagnostics (ASX:COV), according to the Ovarian Cancer Research Foundation (OCRF).


An article from OCRF revealed that the first phase of commercialisation began on August 22, 2023, and focuses on the production of an improved, more accurate diagnostic test for ovarian cancer.

The surgical triage test was funded by the OCRF, developed at the Hudson Institute of Medical Research led by Professor Andrew Stephens and is being commercialised by Cleo Diagnostics.

“This new test will help ensure that an optimal management plan can be put in place early, which will streamline the referral process and provide the best care for patients,” said Cleo Diagnostics lead medical advisor and professor Tom Jobling.

Cleo’s commercialisation efforts aim to lead to better outcomes for patients and save time and resources for the healthcare system. The clinical application of the ovarian cancer test would commence in 2025 upon granting of appropriate regulatory approvals, the article said.

To read the full article, click here.

Click here to connect with Cleo Diagnostics (ASX:COV)) for an Investor Presentation

.

COV:AU
The Conversation (0)
CLEO Further Expands Ovarian Cancer Trial with Siles Health

CLEO Further Expands Ovarian Cancer Trial with Siles Health

Cleo Diagnostics (COV:AU) has announced CLEO Further Expands Ovarian Cancer Trial with Siles Health

Download the PDF here.

The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

Cleo Diagnostics (COV:AU) has announced The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

Download the PDF here.

Invion Limited

Invion Doses First Patient in Phase I/II Non-Melanoma Skin Cancer Trial

Invion Limited (ASX: IVX) (“Invion” or the “Company”) is pleased to announce the dosing of the first patient in its Phase I/II non- melanoma skin cancer (NMSC) trial conducted at Veracity Clinical Research (Veracity) in Brisbane.

Keep reading...Show less
BPH Global

Seaweed Extraction of Critical Minerals R&D

BPH Global (BP8:AU) has announced Seaweed Extraction of Critical Minerals R&D

Download the PDF here.

Resonance Health Ltd

Resonance Contracted by Major Global Pharma Company for Clinical Drug Trial Worth $13.775 Million over 24 Months

Resonance Health Ltd (ASX: RHT) (Resonance or the Company) advises that it has been contracted by Sun Pharmaceutical Industries Limited, an international, publicly listed pharmaceutical company with global operations (Customer) to be the local Australian sponsor, and to provide clinical research organisation (CRO) services, trial site services, and imaging analysis services (collectively, Services), for their clinical trial in Australia of a new drug compound (Clinical Trial).

Keep reading...Show less
  Island Pharmaceuticals

ISLA-101 Phase 2a/b PROTECT Clinical Trial Progress Update

Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce progress on its ISLA-101 Phase 2a/b clinical trial in dengue fever.

Keep reading...Show less

Latest Press Releases

Related News

×